Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunocellular Thera (IMUC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,682
  • Shares Outstanding, K 41,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,310 K
  • 36-Month Beta -0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.43
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/16
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +41,725.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.20 unch
on 09/21/18
0.25 -20.63%
on 08/28/18
-0.03 (-13.04%)
since 08/21/18
3-Month
0.20 unch
on 09/21/18
0.27 -25.93%
on 06/22/18
-0.07 (-25.09%)
since 06/21/18
52-Week
0.03 +566.67%
on 11/30/17
0.55 -63.64%
on 12/14/17
-0.13 (-39.39%)
since 09/21/17

Most Recent Stories

More News
Research Report Identifies Gastar Exploration, Monroe Capital, SandRidge Energy, ImmunoCellular Therapeutics, Inseego, and Digital Turbine with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gastar Exploration Inc. (NYSE:GST),...

IMUC : 0.20 (-3.38%)
MRCC : 13.72 (+0.59%)
SD : 10.98 (-0.81%)
GST : 0.06 (-11.11%)
INSG : 4.09 (+3.28%)
APPS : 1.25 (-0.79%)
ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program,...

IMUC : 0.20 (-3.38%)
Free Technical Research on ImmunoGen and Three More Biotech Equities

Stock Research Monitor: GRFS, HALO, and IMUC

IMUC : 0.20 (-3.38%)
GRFS : 21.13 (-1.22%)
HALO : 17.53 (+1.56%)
ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the first quarter ended March 31, 2018.

IMUC : 0.20 (-3.38%)
Analysis: Positioning to Benefit within DDR, Diamond Offshore Drilling, Energen, ImmunoCellular Therapeutics, Juniper Networks, and ServiceNow -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DDR Corp. (NYSE:DDR), Diamond...

IMUC : 0.20 (-3.38%)
DDR : 13.94 (+0.87%)
JNPR : 29.77 (+0.71%)
NOW : 189.69 (+1.25%)
DO : 19.34 (+5.05%)
EGN : 81.73 (+1.38%)
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material...

IMUC : 0.20 (-3.38%)
ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017 filed with...

IMUC : 0.20 (-3.38%)
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the fourth quarter and full year ended December 31, 2017.

IMUC : 0.20 (-3.38%)
ImmunoCellular Therapeutics, Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 13, 2018 / ImmunoCellular Therapeutics, Ltd. (NYSE American: IMUC) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at...

IMUC : 0.20 (-3.38%)
Today's Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / U.S. markets had a topsy-turvy day as concerns of a potential trade war, a result of tariffs proposed by President Donald Trump, continue to worry investors....

IMUC : 0.20 (-3.38%)
SPPI : 21.36 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade IMUC with:

Business Summary

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens,...

See More

Key Turning Points

2nd Resistance Point 0.22
1st Resistance Point 0.21
Last Price 0.20
1st Support Level 0.20
2nd Support Level 0.19

See More

52-Week High 0.55
Fibonacci 61.8% 0.35
Fibonacci 50% 0.29
Fibonacci 38.2% 0.23
Last Price 0.20
52-Week Low 0.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar